
Opinion|Videos|August 5, 2024
Third-line Treatment Options for DLBCL After CAR T-cell Therapy or ASCT in Second-line
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please give an overview of treatment options for a patient who received 2L treatment with either CAR T-cell therapy or ASCT and has relapsed.
- What would be your treatment choice in the third line?
- What key issues do you consider in your sequencing decisions?
- Please discuss rationales for each:
- Monoclonal antibody—tafasitamab?
- ADC —loncastuximab, polatuzumab?
- Would you go to CAR T after ASCT?
- Bispecific antibody—epcoritamab or glofitamab?
Advertisement
Related to this article

Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.

The Pan-Mass Challenge donated a record $80 million to Dana-Farber Cancer Institute to support cancer research, treatment, and patient care.

Onvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
3
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
4
Cretostimogene Grenadenorepvec Improves RFS in Intermediate-Risk and High-Grade Ta NMIBC
5

